Robot-assisted Endoscope Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By End User (Hospitals, Outpatient Facilities, Others), By Region, and By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.51 Billion
CAGR (2026-2031)	7.73%
Fastest Growing Segment	Outpatient Facilities
Largest Market	North America
Market Size (2031)	USD 2.36 Billion

Market Overview

The Global Robot-assisted Endoscope Market will grow from USD 1.51 Billion in 2025 to USD 2.36 Billion by 2031 at a 7.73% CAGR. Robot-assisted endoscopes are electromechanical devices designed to enhance the capabilities of physicians during diagnostic and therapeutic gastrointestinal procedures by providing improved stability, visualization, and dexterity compared to traditional manual instruments. The expansion of this market is primarily supported by the rising prevalence of chronic digestive disorders and a growing preference for minimally invasive interventions that reduce hospitalization times. Illustrating the significant disease burden driving this demand, the American Cancer Society reported that in 2024, approximately 152,810 new cases of colorectal cancer were estimated to be diagnosed in the United States alone.

Despite these robust growth drivers, the market faces a significant impediment regarding the high capital acquisition and maintenance costs associated with robotic platforms. This financial barrier limits adoption rates, particularly among smaller healthcare facilities and in developing regions where reimbursement frameworks may be insufficient. Furthermore, the substantial learning curve required for medical professionals to master these complex systems creates an operational bottleneck. These economic and training constraints continue to challenge the widespread integration of robot-assisted technologies into standard clinical practice.

Key Market Drivers

Technological advancements in artificial intelligence and the development of flexible robotic platforms are fundamentally reshaping the Global Robot-assisted Endoscope Market by enabling access to previously unreachable anatomical structures. Innovations in soft robotics and steerable catheters allow physicians to navigate tortuous pathways in the lungs and gastrointestinal tract with greater stability and precision than manual instruments. This technical progress is validating the safety of complex platforms and accelerating their path to commercialization. A notable development occurred when, according to EndoQuest Robotics, December 2024, in a press release regarding its pivotal clinical study, the U.S. FDA granted an Investigational Device Exemption (IDE) for the company's flexible Endoluminal Surgical System to begin trials for colorectal procedures. Such regulatory milestones confirm the maturity of these advanced technologies, encouraging broader adoption among healthcare facilities seeking to enhance their diagnostic capabilities.

The increasing prevalence of pulmonary and gastrointestinal disorders significantly fuels market expansion as healthcare providers face growing pressure to perform biopsies and therapeutic interventions with minimal trauma. The rising incidence of complex conditions such as lung cancer necessitates advanced diagnostic tools that can deliver higher yield rates for early-stage detection, driving the utilization of robot-assisted bronchoscopy. Illustrating this burden, according to the American Lung Association, November 2024, in the '2024 State of Lung Cancer' report, it was projected that approximately 235,000 new cases of lung cancer would be diagnosed in the United States in 2024. This escalating disease volume directly translates into higher procedure counts for established robotic platforms. Consequently, according to Intuitive Surgical, October 2024, in its third-quarter financial results, the procedure volume for the Ion endoluminal system grew by approximately 73% compared to the same quarter of the previous year, underscoring the rapid clinical integration of these technologies to address critical patient needs.

Download Free Sample Report

Key Market Challenges

The primary impediment hampering the growth of the Global Robot-assisted Endoscope Market is the high capital acquisition and maintenance costs associated with these advanced platforms. This substantial financial burden restricts market penetration, particularly within smaller community hospitals and ambulatory surgical centers operating on thin margins. When healthcare facilities face budget constraints, they often prioritize essential operational expenses over investing in premium, high-cost technologies that lack robust reimbursement pathways. Consequently, the inability to justify the return on investment for these expensive systems directly stalls the broader adoption of robot-assisted endoscopy.

This economic pressure is evidenced by recent industry data highlighting the financial strain on healthcare providers. According to the American Hospital Association, in 2024, the average age of hospital plant and capital equipment increased by over 10% as facilities were forced to delay purchasing new medical technologies due to rising operational costs and insufficient reimbursement. This contraction in capital spending power directly negatively impacts the robot-assisted endoscope market, as healthcare administrators are compelled to defer or cancel the acquisition of such high-value electromechanical devices in favor of maintaining existing, lower-cost manual instruments.

Key Market Trends

The development of telesurgery and remote clinical monitoring solutions is expanding the availability of specialized gastrointestinal care by overcoming geographical limitations. Advanced robotic systems integrated with low-latency communication networks now allow expert physicians to manipulate endoscopes from distant locations, ensuring that patients in underserved regions can receive timely interventions without the need for travel. This capability is particularly vital for complex procedures where the requisite technical expertise is concentrated in major medical centers, democratizing access to high-quality diagnostics. Validating this remote potential, according to Healthcare IT News, September 2024, researchers from the Chinese University of Hong Kong and ETH Zurich successfully conducted a biopsy on a live porcine model over a distance of 5,700 miles, controlling a magnetic endoscope in Hong Kong from a console in Switzerland.

Simultaneously, the emergence of autonomous navigation and magnetic steering capabilities is revolutionizing the invasiveness and workflow of endoscopic examinations. Unlike traditional manually pushed instruments or mechanically actuated catheters, these next-generation platforms utilize external magnetic fields to precisely guide ingestible capsules or soft scopes through the digestive tract, significantly reducing patient discomfort and often eliminating the need for sedation. This shift toward magnetically driven, tether-free mobility minimizes tissue trauma and streamlines the procedural footprint, facilitating use in diverse clinical settings. Highlighting the commercial momentum of this technology, according to The Robot Report, June 2024, Endiatx announced it had secured $7 million in funding to advance the clinical development of its PillBot system, a swallowable robotic capsule that physicians can actively steer inside the stomach.

Segmental Insights

The Outpatient Facilities segment has emerged as the fastest-growing category in the Global Robot-assisted Endoscope Market, driven by the increasing preference for ambulatory care settings. This trend is underpinned by the cost-effectiveness of performing procedures outside of traditional hospitals, which significantly lowers healthcare expenditures. Additionally, the development of compact robotic systems has allowed these facilities to adopt advanced technology without requiring extensive infrastructure. Regulatory support, including clearances from the U.S. Food and Drug Administration for specific outpatient-focused devices, further accelerates this adoption, allowing providers to offer minimally invasive treatments that ensure quicker patient recovery and operational efficiency.

Regional Insights

North America maintains a leading position in the Global Robot-assisted Endoscope Market due to its established healthcare infrastructure and widespread adoption of minimally invasive technologies. This dominance is primarily driven by a supportive regulatory environment, where the U.S. Food and Drug Administration (FDA) facilitates the approval of new robotic devices. Furthermore, the region benefits from structured reimbursement policies that allow healthcare facilities to invest in automated endoscopic systems. High healthcare expenditure and the growing prevalence of gastrointestinal disorders requiring precise diagnostics also contribute to North America holding the largest market share globally.

Recent Developments

• In October 2025, Intuitive Surgical secured FDA clearance for a suite of software enhancements for its Ion endoluminal system, a robotic-assisted platform for minimally invasive lung biopsy. The update incorporated artificial intelligence throughout the navigational workflow and integrated advanced imaging features to improve procedure precision. These technical advancements were designed to mitigate issues such as CT-to-body divergence, allowing for more accurate targeting of pulmonary nodules during biopsies. The company highlighted that these innovations aimed to streamline the workflow for physicians and support the early diagnosis of lung cancer through more effective robotic-assisted interventions.
• In September 2025, Virtuoso Surgical announced that the U.S. Food and Drug Administration had granted Breakthrough Device Designation to its Virtuoso Surgical Robotic System. This designation was specifically awarded for the system’s application in the removal of bladder lesions through en bloc excision. The regulatory recognition acknowledged the potential of the device to offer substantial advantages over existing treatment standards for debilitating conditions. The system utilizes needle-sized robotic manipulators to provide surgeons with exceptional dexterity and control at the tip of a rigid endoscope, enabling complex procedures to be performed within confined anatomical spaces.
• In March 2025, Johnson & Johnson MedTech received 510(k) clearance from the U.S. Food and Drug Administration for a significant software update to its Monarch platform. This new release integrated artificial intelligence algorithms and advanced imaging capabilities into the robotic-assisted bronchoscopy system. The enhanced software was developed to improve navigational accuracy during peripheral lung biopsies by helping physicians precisely locate and access small, difficult-to-reach nodules. This regulatory clearance represented a strategic expansion of the Monarch platform’s digital capabilities, reinforcing the company's commitment to improving diagnostic yields and clinical outcomes in the fight against lung cancer.
• In December 2024, EndoQuest Robotics announced that it had received an Investigational Device Exemption from the U.S. Food and Drug Administration to begin a pivotal clinical trial for its Flexible Robotic System. This regulatory milestone enabled the commencement of the PARADIGM study, a multi-center trial aimed at validating the safety and efficacy of the platform for removing colorectal lesions. The robotic system is designed to perform endoluminal surgeries through natural body orifices, eliminating external incisions. This development marked a critical step toward the commercialization of the technology, offering a scar-free alternative to conventional laparoscopic methods for gastrointestinal interventions.

Key Market Players

• Asensus Surgical Inc
• Intuitive Surgical Inc
• Auris Health Inc
• Johnson & Johnson Services, Inc.
• Brainlab AG
• Medtronic PLC
• Boston Scientific Corp
• Stryker Corp

By End User	By Region
Hospitals Outpatient Facilities Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Robot-assisted Endoscope Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Robot-assisted Endoscope Market, By End User:

• Hospitals
• Outpatient Facilities
• Others

• Robot-assisted Endoscope Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE